A new treatment for atopic dermatitis has been approved by the FDA, offering hope to those with moderate-to-severe eczema. The drug, EBGLYSS from Eli Lilly, targets the primary driver behind the condition – a cytokine that causes inflammation and itching. This drug is now available for adults and children over 12 years old who have moderate-to-severe atopic dermatitis.
Atopic dermatitis, also known as eczema, is a condition characterized by itchy and inflamed skin that can be debilitating. It often appears on the arms or behind the knees, but can affect any part of the body. Scratching the affected skin can lead to redness, swelling, cracking, and weeping of clear fluid or blood. In severe cases, the skin may crust over and scale as it heals, leading to further discomfort.
Individuals with a family history of atopic dermatitis or other allergies are more likely to develop the condition. It is more common in girls and women, as well as Hispanic and Black children. While it often appears during infancy or childhood, it can occur at any age. Finding an effective treatment for atopic dermatitis can be challenging, but EBGLYSS offers a promising new option.
Dr. Tien Nguyen, a dermatologist involved in clinical trials for EBGLYSS, explained that atopic dermatitis is caused by pro-inflammatory cytokines that trigger itching and inflammation. IL-13 is considered the primary driver of the condition, which EBGLYSS targets to reduce symptoms. Other drugs on the market also target cytokines related to atopic dermatitis, but not all are effective for everyone. Having a new drug like EBGLYSS that specifically targets IL-13 is a valuable addition to dermatological treatments.
The FDA approved EBGLYSS based on the results of clinical trials that showed significant improvement in skin condition for participants. The drug is administered through injections and has shown positive outcomes in reducing itching and inflammation. While some side effects like eye inflammation and injection site reactions were reported, the overall benefits of EBGLYSS outweighed these concerns for many patients.
Living with atopic dermatitis can be extremely challenging, affecting both physical comfort and emotional well-being. Patients who have received treatment with drugs like EBGLYSS have reported a significant improvement in their symptoms, leading to better sleep, reduced flareups, and improved quality of life. With the approval of new drugs like EBGLYSS, dermatologists can offer more effective and tailored treatments to help patients manage their condition and regain confidence in their daily lives.
